Please use this search facility to search all content found within the website:

86 results:

Extension to TerugBetaalRegeling Acecort®

Extension to TerugBetaalRegeling Acecort® Recently also Acecort® 2 and 3 mg tablets have been registered. The health insurer will not reimburse the cost in full. The producer of this medicine…

Privacy information

There are no tracking cookies being placed via this website. The Company also does not process any personal data from your visit to this website. Therefore, you will not find either a cookie notice…

Renewal reimbursement scheme Forxiga® (dapagliflozine) 10 mg and Xigduo (dapagliflozine & metformine HCI) 5 mg

Renewal reimbursement scheme Forxiga® (dapagliflozine) 10 mg and Xigduo (dapagliflozine & metformine HCI) 5 mg The Reimbursement Solution TerugBetaalRegeling (TBR) of Forxiga® (dapagliflozine) 10…

Cholestagel®

General information The pharmacist has dispensed Cholestagel® 625mg to the patient. The health insurer will not reimburse the cost of this prescription in full. The producer of this…

Termination TerugBetaalRegeling Tecfidera®

Termination TerugBetaalRegeling Tecfidera® As of December 1, 2021, a Personal Contribution for Tecfidera is no longer required. Health insurers will once again fully reimburse the medicine. The…

Termination TerugBetaalRegeling Fragmin®2500

Termination TerugBetaalRegeling Fragmin®2500 From January 1st 2022 onwards, the reimbursement scheme for FRAGMIN (dalteparine)2500 INJVLST 12.500IE/ML WWSP 0,2ML will be terminated. The…

Metoject Pen®

General information The pharmacist has dispensed Metoject Pen® 7.5mg to the patient. The health insurer will not reimburse the cost of this prescription in full. The producer of this…

Broxil®

General information The pharmacist has dispensed Broxil® 125 mg / 5 mL, powder for oral suspension to the patient. The health insurer will not reimburse the cost of this prescription in full.…

Reimbursement Scheme Forxiga® (dapagliflozin) 10 mg for patients with diabetes partially stopped

Reimbursement Scheme Forxiga® (dapagliflozin) 10 mg for patients with diabetes partially stopped From September 1st 2021 onwards, Forxiga® (dapagliflozin) 10 mg for the treatment of adults with type…

Reimbursement Scheme Forxiga® (dapagliflozine) 10 mg - Chronic Kidney Disease

Reimbursement Scheme Forxiga® (dapagliflozine) 10 mg - Chronic Kidney Disease The health insurer does not yet fully reimburse Forxiga® (dapagliflozine) 10 mg for the treatment of chronic kidney…

You are currently offline. Some pages or content may fail to load.